BackNasus Pharma Overview

Nasus Pharma Accounts Payable

Track Nasus Pharma's accounts payable ($350K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$347000.00
↓ 47.74% YoYΔ $-317000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Nasus Pharma Accounts Payable History

Loading

Nasus Pharma vs. peers: Accounts Payable Comparison

Loading

Nasus Pharma Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Nasus Pharma (NSRX) FAQ

The latest accounts payable for NSRX is $350K as of June 2026. That compares with $660K in the prior-year period — down 47.7% year over year. Investors often review this figure alongside Nasus Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, NSRX's accounts payable moved from $660K to $350K — a 47.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nasus Pharma's operating scale or balance-sheet position.

A accounts payable figure of $350K for NSRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NSRX's accounts payable ($350K), review year-over-year change from $660K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.